Viability Of Sulzer Inter-Op Proposed Class Action Settlement In Doubt
This article was originally published in The Gray Sheet
Executive Summary
A preliminary federal appeals court decision allowing individual Inter-Op hip shells and Natural Knee II implant lawsuits to proceed, combined with a sagging price in Sulzer Medica stock, may doom the firm's proposed $783 mil. class action settlement, forcing Sulzer to seek protection under federal bankruptcy laws
You may also be interested in...
Inter-Op Settlement Stays $15.5 Mil. In Damages; State Plaintiffs Appeal
Sulzer Medica is relying on an anticipated class settlement to impose a seven-year freeze on hip and knee revision damages already being awarded at the state court level.
Sulzer Biologics Ne-Osteo U.S. Fusion Filing Awaits Marketing Agreement
Sulzer Biologics says it will find a U.S. distribution partner for the Ne-Osteo Spine bone morphogenic protein prior to pursuing FDA approval for use in spinal fusion.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.